Skye Bioscience, Inc. — Director's Dealing 2021

Jul 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2021-07-22

Reporting Person: TYLE PRAVEEN (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-22	Director Option Grant (Right to Buy)	$0.14	A	250000	Acquired	2031-07-22	Common Stock (250000)	Direct

Footnotes

F1: Each of the Options shall be exercisable for a price of $0.14 per Option Share for ten years from July 22, 2021 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years.